Imugene Ltd

IMU

Company Profile

  • Business description

    Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.

  • Contact

    4-6 Bligh Street
    Suite 12.01, Level 12
    SydneyNSW2000
    AUS

    T: +61 294230881

    https://www.imugene.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    5

Stocks News & Analysis

stocks

Nvidia: Collaboration with Intel might bring some goodwill with the US

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks

What now for Santos after takeover offer collapses?

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks

Morningstar initiates coverage on small cap ASX REIT

Coverage of ASX listed REIT as investor interest in property continues to grow.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,061.2061.30-0.67%
CAC 407,853.591.02-0.01%
DAX 4023,639.4135.12-0.15%
Dow JONES (US)46,315.27172.850.37%
FTSE 1009,216.6711.44-0.12%
HKSE26,545.10106.590.40%
NASDAQ22,631.48160.750.72%
Nikkei 22545,045.81143.540.32%
NZX 50 Index13,219.5612.10-0.09%
S&P 5006,664.3632.400.49%
S&P/ASX 2008,773.5075.00-0.85%
SSE Composite Index3,820.0911.57-0.30%

Market Movers